Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

December 31, 2005

Study Completion Date

February 28, 2007

Conditions

Hereditary Angioedema (HAE)

Interventions

DRUG

ecallantide

dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.

DRUG

Phosphate Buffer Saline (PBS),

given as three 1mL subcutaneous injections.

Trial Locations (1)

Institute for Asthma and Allergy, Wheaton